Lifecore Biomedical(LFCR.US)

Company Encyclopedia
View More
name
Lifecore Biomedical
LFCR.US
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacture of hyaluronate acid in bulk form; and formulated and filled syringes, cartridges, and vials for injectable products used in treating a range of medical conditions and procedures. It also provides product development services include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and production of materials for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc.
760.75 B
LFCR.USMarket value -Rank by Market Cap -/-

Financial Score

01/01/2026 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking51/62
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-701.27%E
    • Profit Margin-30.04%E
    • Gross Margin31.27%C
  • Growth ScoreD
    • Revenue YoY0.47%C
    • Net Profit YoY-469.26%E
    • Total Assets YoY-5.76%D
    • Net Assets YoY-12.00%E
  • Cash ScoreD
    • Cash Flow Margin-290.51%D
    • OCF YoY0.47%C
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreE
    • Gearing Ratio80.18%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lifecore Biomedical (LFCR) Projected to Post Quarterly Earnings on Thursday

    Lifecore Biomedical (NASDAQ:LFCR) is set to release its Q2 2026 earnings after market close on January 1. Analysts expect earnings of ($0.11) per share and revenue of $35.308 million. The company previously reported a negative EPS of ($0.22) and revenue of $26.54 million. Lifecore's stock opened at $8.24 with a market cap of $308.75 million. Analysts have given it a consensus 'Hold' rating with an average price target of $6.00. Institutional investors hold 83.36% of the stock.

    Market Beat·
    US
    LFCR
    +1.11%
    Market Beat·
    US
    LFCR
    +1.11%

    12:30 ET HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

    Halper Sadeh LLC, an investor rights law firm, is investigating potential breaches of fiduciary duties by Lifecore Biomedical, Inc.'s officers and directors. Shareholders are encouraged to contact the firm to discuss their rights, as they may seek corporate governance reforms or other relief. The firm operates on a contingent fee basis, emphasizing the importance of shareholder involvement in improving company policies and enhancing shareholder value.

    prnewswire·
    US
    LFCR
    +1.11%
    prnewswire·
    US
    LFCR
    +1.11%

    NY law firm Halper Sadeh LLC urges Lifecore Biomedical, Inc. (NASDAQ: LFCR) shareholders to discuss their rights promptly.

    Investors are urged to get in touch with the company promptly as there may be a restricted window to assert your rights. On December 24, 2025, Halper Sadeh LLC, a legal firm specializing in investor rights, disclosed that they are looking into potential misconduct involving specific executives and board members of Lifecore Biomedical, Inc. (Nasdaq: LFCR).

    Unusual Whales·
    US
    LFCR
    +1.11%
    Unusual Whales·
    US
    LFCR
    +1.11%

    Lifecore Biomedical Joins Nasdaq Biotech Index

    Lifecore Biomedical Inc. (NASDAQ: LFCR) will be added to the Nasdaq Biotech Index (NBI) on December 22, 2025, following the index's annual reconstitution. The company met eligibility criteria including market capitalization, trading volume, and public company seasoning.

    Reuters·
    US
    LFCR
    +1.11%
    Reuters·
    US
    LFCR
    +1.11%

    Lifecore Biomedical shares are trading higher after the company announced that it has signed a CDMO master services agreement with a global pharmaceutical customer.

    benzinga_article·
    US
    LFCR
    +1.11%
    benzinga_article·
    US
    LFCR
    +1.11%
    © 2026 Longbridge｜Disclaimer